Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Hartmut Döhner, Elihu Estey, David Grimwade...
https://pubmed.ncbi.nlm.nih.gov/27895058/Actively Recruiting
Led by Guangzhou Lupeng Pharmaceutical Company LTD. · Updated on 2026-09-11
198
Participants Needed
3
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and pharmacokinetics of LP-108, a BCL-2 inhibitor, combined with azacitidine in adults with acute myeloid leukemia AML, myelodysplastic syndromes MDS, or chronic myelomonocytic leukemia CMML. This Phase 1, open-label, multicenter study aims to determine the recommended Phase 2 dose and assess early signs of effectiveness in these conditions. Participants receive LP-108 orally for 21 or 28 days within a 28-day cycle, with azacitidine administered subcutaneously for 7 days each cycle starting on day 1, except during an initial ramp-up cycle. The study includes dose escalation and expansion phases, where dosing schedules are adjusted to identify tolerable and effective doses. Participants continue treatment until disease progression, unacceptable side effects, or other reasons for withdrawal. Strong or moderate CYP3A inhibitors and inducers are not allowed during the study. During the study, participants undergo screening to confirm eligibility and have regular blood and bone marrow tests. Researchers monitor safety events, pharmacokinetic parameters such as maximum concentration and half-life of LP-108, and response to treatment. Outcomes measured include maximum tolerated dose, objective response rate, progression-free survival, and overall survival, with follow-up lasting up to five years. Treatment and safety are closely monitored throughout the study duration.
CONDITIONS
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Y
Yue Shen, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Guangzhou Lupeng Pharmaceutical Company LTD.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Indefinitely until disease progression or withdrawal
Participants receive LP-108 orally and azacitidine by injection in 28-day cycles. LP-108 dosing may be adjusted during dose escalation and expansion phases. Treatment continues until disease progression, unacceptable side effects, or withdrawal.
Regular visits during each treatment cycle
Duration - Up to 5 years
Researchers monitor safety, response, and survival outcomes up to five years after treatment completion.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Hartmut Döhner, Elihu Estey, David Grimwade...
https://pubmed.ncbi.nlm.nih.gov/27895058/Bruce D Cheson, Peter L Greenberg, John M Bennett...
https://pubmed.ncbi.nlm.nih.gov/16609072/Michael R Savona, Luca Malcovati, Rami Komrokji...
https://pubmed.ncbi.nlm.nih.gov/25624319/Guangzhou Lupeng Pharmaceutical Company LTD.
Lead Sponsor